Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.52 |
| ▸ | MDH2 | P40926 | 3/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.45 |
| ▸ | MDH1 | P40925 | 2/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628438 | 0.88 | HIF1A (0.54) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL19357423 | 0.85 | HIF1A (0.55) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL20482361 | 0.84 | HIF1A (0.51) | HIF1AMDH2EPAS1PPARGPPARD | |
| SCHEMBL21628459 | 0.83 | HIF1A (0.50) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL21656769 | 0.83 | STS (0.47) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL21656934 | 0.83 | SLC6A2 (0.46) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL21628797 | 0.82 | HIF1A (0.48) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL21628401 | 0.81 | HDAC6 (0.48) | HIF1AMDH2EPAS1MDH1EP300 | |
| SCHEMBL21628841 | 0.81 | OPRM1 (0.40) | — | |
| SCHEMBL21628569 | 0.80 | IGFBP3 (0.48) | KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HIF1A 2000/4885MDH2 1235/4885EPAS1 870/4885 |
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | HIF1A 1618/4885MDH2 1193/4885EPAS1 982/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HIF1A 2000/4885MDH2 1235/4885EPAS1 870/4885 |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HIF1A 2000/4885MDH2 1235/4885EPAS1 870/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HIF1A 2000/4885MDH2 1235/4885EPAS1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.